Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,764 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Refractory Neoplasm Clear all
Recruiting Phase 1Phase 2 Interventional

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

NCT06090539
View directory record Official record
Conditions
Relapsed/Refractory Non-Hodgkin Lymphoma
Interventions
BMS-986458, Rituximab, Glofitamab/Obinutuzumab, Mosunetuzumab, Epcoritamab, Golcadomide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
11
States / cities
Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 20, 2026, 5:36 AM EDT
Recruiting Phase 1 Interventional

IDOV-Immune for Advanced Solid Tumors

NCT06910657
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Cancer, Sarcoma, Bladder Cancer, Lung Cancer, Prostate Cancer, Cervical Cancers, Head and Neck Cancers, Adrenal Gland Tumors
Interventions
IDOV-Immune (oncolytic vaccinia virus)
Biological
Lead sponsor
ViroMissile, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
St Louis, Missouri • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 20, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

NCT02159365
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
29
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Bakersfield, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 20, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Sitagliptin Umbilical Cord Blood Transplant Study

NCT00862719
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Acute Lymphoblastic Leukemia, Myelodysplasia, Leukemia, Myelogenous, Chronic, Lymphoma, Non-Hodgkin
Interventions
Sitagliptin
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 59 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 20, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors

NCT03638167
View directory record Official record
Conditions
Central Nervous System Tumor, Pediatric, Glioma, Ependymoma, Medulloblastoma, Germ Cell Tumor, Atypical Teratoid/Rhabdoid Tumor, Primitive Neuroectodermal Tumor, Choroid Plexus Carcinoma, Pineoblastoma
Interventions
EGFR806-specific chimeric antigen receptor (CAR) T cell
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 26 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 20, 2026, 5:36 AM EDT
Completed Phase 2 Interventional

Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT00028600
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
filgrastim, CD34+ cells, cyclophosphamide, fludarabine phosphate, melphalan, methotrexate, tacrolimus
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Up to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
15
States / cities
San Francisco, California • Lewes, Delaware • Newark, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 20, 2026, 5:36 AM EDT
Not listed Phase 1Phase 2 Interventional

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma

NCT01541332
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide, Pegylated Liposomal Doxorubicin (PLD), Dexamethasone
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
8
States / cities
Burbank, California • Encinitas, California • Fresno, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 20, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma

NCT00132028
View directory record Official record
Conditions
Adult Favorable Prognosis Hodgkin Lymphoma, Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Adult Unfavorable Prognosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma
Interventions
vorinostat, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 20, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

Ecteinascidin 743 in Treating Children With Refractory Solid Tumors

NCT00006463
View directory record Official record
Conditions
Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ECTEINASCIDIN 743
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
42
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2014 · Synced Oct 20, 2026, 5:36 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma

NCT02229981
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Kaposi Sarcoma
Interventions
ABC294640
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 20, 2026, 5:36 AM EDT
Active, not recruiting Phase 1 Interventional

RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists

NCT02112565
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
RNR inhibitor COH29, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 20, 2026, 5:36 AM EDT
Withdrawn Phase 2 Interventional

MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma

NCT00298467
View directory record Official record
Conditions
Lymphoma, Large-Cell
Interventions
MDX-060
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
7
States / cities
Duarte, California • Fresno, California • La Jolla, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2010 · Synced Oct 20, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

NCT01301807
View directory record Official record
Conditions
Non-Secretory Plasma Cell Myeloma, Plasmacytosis, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Carfilzomib, Panobinostat
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 20, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)

NCT00593944
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
MDX-1342
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Boston, Massachusetts • Buffalo, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 20, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma

NCT00768144
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Sunitinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 20, 2026, 5:36 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML

NCT05503134
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Universal Donor Natural Killer Cells
Biological
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Year to 24 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 20, 2026, 5:36 AM EDT
Terminated Phase 2 Interventional Results available

Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

NCT01391611
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor (GIST)
Interventions
Pazopanib
Drug
Lead sponsor
Kristen Ganjoo
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 20, 2026, 5:36 AM EDT
Withdrawn No phase listed Observational

Long-term Registry of Patients Treated With Loncastuximab Tesirine

NCT05160064
View directory record Official record
Conditions
B-Cell Lymphomas
Interventions
Not listed
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Fountain Valley, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 20, 2026, 5:36 AM EDT
Terminated Phase 1 Interventional

An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)

NCT01742793
View directory record Official record
Conditions
Hodgkin's Lymphoma, Mature T-cell Lymphoma, Multiple Myeloma
Interventions
lenalidomide (Revlimid) and romidepsin (Istodax)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 20, 2026, 5:36 AM EDT
Terminated Phase 1 Interventional Results available

Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT02882321
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Oxidative Phosphorylation Inhibitor IACS-010759, Pharmacological Study
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 20, 2026, 5:36 AM EDT
Not listed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005992
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSA prostate cancer vaccine, therapeutic autologous dendritic cells
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 20, 2026, 5:36 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment

NCT01830816
View directory record Official record
Conditions
Multiple Myeloma, Advanced Solid Tumors
Interventions
Ixazomib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
Atlanta, Georgia • Peoria, Illinois • Fairway, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 20, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma

NCT01016730
View directory record Official record
Conditions
AIDS-Related Kaposi Sarcoma, HIV Infection, Recurrent Kaposi Sarcoma
Interventions
Bortezomib, Laboratory Biomarker Analysis, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
9
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 20, 2026, 5:36 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

NCT00479167
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Bortezomib and Tositumomab I-131
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 20, 2026, 5:36 AM EDT